Angiochem, Xinogen in China deal

Angiochem Inc. (Montreal, Quebec) granted an exclusive license in China to Xinogen Hong Kong Pharma Co. Ltd. to develop and commercialize ANG1005 to treat leptomeningeal carcinomatosis and brain metastases arising from metastatic breast cancer. The therapy is a peptide (Angiopep-2) conjugated to three paclitaxel molecules for receptor-mediated transport into the brain.

Angiochem will receive an upfront payment and is eligible for milestones and royalties. Details were not disclosed. Xinogen is a subsidiary of Shenogen Pharma Group Ltd. (Beijing, China)...